Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Melatonin Receptor 1 as a target for antidepressant drugs
EF 2013-14
Résumé
Affecting more than 350 million people globally, depression is one of the most widespread mental disorders in the world. Depression is characterized by low mood, anhedonia, anxiety, fatigue, negative thoughts, and is frequently accompanied by changes in circadian rhythms of behaviour, sleep, core temperature and hormone secretion. Current antidepressant drugs alter the brain levels of the monoamines serotonin, norepinephrine, and dopamine. However, these treatments only effectively treat depression in a third of patients, and often cause serious side effects. Thus it is critical to investigate and validate alternative targets for the development of novel antidepressant treatments. One promising new target is the melatonergic system. Melatonin acts through its receptors MT1 and MT2 in mammals, but their individual and combined effects on mood and behaviour are still poorly understood. This is in part due to the lack of selective MT1 or MT2 receptor agonists. Excitingly, a novel selective MT1 agonist has recently been synthesized, and will be tested via behavioural assays and in vivo electrophysiological approaches in mice and rats, to investigate the specific role of MT1 receptors in depression. The results will validate MT1 as a novel target for the development of alternative antidepressant drugs.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
311997
Name
Posner Ada R
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Melatonin Receptor 1 as a target for antidepressant drugs
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antidepressants; Behaviour; Depression; Drug Discovery; Electrophysiology; Melatonin; Mood; Neuroscience; Psychiatry; Rodents
Abstract
Affecting more than 350 million people globally, depression is one of the most widespread mental disorders in the world. Depression is characterized by low mood, anhedonia, anxiety, fatigue, negative thoughts, and is frequently accompanied by changes in circadian rhythms of behaviour, sleep, core temperature and hormone secretion. Current antidepressant drugs alter the brain levels of the monoamines serotonin, norepinephrine, and dopamine. However, these treatments only effectively treat depression in a third of patients, and often cause serious side effects. Thus it is critical to investigate and validate alternative targets for the development of novel antidepressant treatments. One promising new target is the melatonergic system. Melatonin acts through its receptors MT1 and MT2 in mammals, but their individual and combined effects on mood and behaviour are still poorly understood. This is in part due to the lack of selective MT1 or MT2 receptor agonists. Excitingly, a novel selective MT1 agonist has recently been synthesized, and will be tested via behavioural assays and in vivo electrophysiological approaches in mice and rats, to investigate the specific role of MT1 receptors in depression. The results will validate MT1 as a novel target for the development of alternative antidepressant drugs.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Posner, Ada R
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~